Literature DB >> 20385357

The TRIP from ULF to ARF.

Manuel Collado1, Manuel Serrano.   

Abstract

ARF is a key activator of p53, and together they form a critical duo for protection against cancer. Previous evidence had recognized the regulatory potential of ubiquitin-mediated degradation of ARF. The recent identification of TRIP12/ULF as a ubiquitin ligase of ARF adds an important missing piece to the ARF/p53 pathway. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20385357     DOI： 10.1016/j.ccr.2010.03.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  11 in total

1.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

2.  Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.

Authors:  Norio Shiba; Kenichi Yoshida; Yusuke Hara; Genki Yamato; Yuichi Shiraishi; Hidemasa Matsuo; Yusuke Okuno; Kenichi Chiba; Hiroko Tanaka; Taeko Kaburagi; Masanobu Takeuchi; Kentaro Ohki; Masashi Sanada; Jun Okubo; Daisuke Tomizawa; Tomohiko Taki; Akira Shimada; Manabu Sotomatsu; Keizo Horibe; Takashi Taga; Souichi Adachi; Akio Tawa; Satoru Miyano; Seishi Ogawa; Yasuhide Hayashi
Journal:  Blood Adv       Date:  2019-10-22

3.  TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease.

Authors:  Bo Am Seo; Donghoon Kim; Heehong Hwang; Min Seong Kim; Shi-Xun Ma; Seung-Hwan Kwon; Sin Ho Kweon; Hu Wang; Je Min Yoo; Seulah Choi; Sang Ho Kwon; Sung-Ung Kang; Tae-In Kam; Kwangsoo Kim; Senthilkumar S Karuppagounder; Bong Gu Kang; Saebom Lee; Hyejin Park; Sangjune Kim; Wei Yan; Yong-Shi Li; Sheng-Han Kuo; Javier Redding-Ochoa; Olga Pletnikova; Juan C Troncoso; Gabsang Lee; Xiaobo Mao; Valina L Dawson; Ted M Dawson; Han Seok Ko
Journal:  Neuron       Date:  2021-10-12       Impact factor: 17.173

4.  RNA-Seq analysis identifies aberrant RNA splicing of TRIP12 in acute myeloid leukemia patients at remission.

Authors:  Panke Gao; Zhen Jin; Yingying Cheng; Xiangshan Cao
Journal:  Tumour Biol       Date:  2014-06-25

5.  TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.

Authors:  L Wang; P Zhang; D P Molkentine; C Chen; J M Molkentine; H Piao; U Raju; J Zhang; D R Valdecanas; R C Tailor; H D Thames; T A Buchholz; J Chen; L Ma; K A Mason; K-K Ang; R E Meyn; H D Skinner
Journal:  Oncogene       Date:  2016-07-18       Impact factor: 9.867

6.  Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma.

Authors:  Guiyuan Li; Shengming Yi; Fan Yang; Yongxin Zhou; Qiang Ji; Jianzhi Cai; Yunqing Mei
Journal:  Thorac Cancer       Date:  2014-04-22       Impact factor: 3.500

7.  The oncogenic E3 ligase TRIP12 suppresses epithelial-mesenchymal transition (EMT) and mesenchymal traits through ZEB1/2.

Authors:  Kwok Kin Lee; Deepa Rajagopalan; Shreshtha Sailesh Bhatia; Roberto Tirado-Magallanes; Wee Joo Chng; Sudhakar Jha
Journal:  Cell Death Discov       Date:  2021-05-07

Review 8.  Dual Role of the Alternative Reading Frame ARF Protein in Cancer.

Authors:  Rosa Fontana; Michela Ranieri; Girolama La Mantia; Maria Vivo
Journal:  Biomolecules       Date:  2019-03-04

9.  A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.

Authors:  Rebecca Hein; Dieter Flesch-Janys; Norbert Dahmen; Lars Beckmann; Sara Lindström; Nils Schoof; Kamila Czene; Kirstin Mittelstraß; Thomas Illig; Petra Seibold; Sabine Behrens; Keith Humphreys; Jingmei Li; Jianjun Liu; Janet E Olson; Xianshu Wang; Susan E Hankinson; Thérèse Truong; Florence Menegaux; Isabel Dos Santos Silva; Nichola Johnson; Shou-Tung Chen; Jyh-Cherng Yu; Argyrios Ziogas; Vesa Kataja; Veli-Matti Kosma; Arto Mannermaa; Hoda Anton-Culver; Chen-Yang Shen; Hiltrud Brauch; Julian Peto; Pascal Guénel; Peter Kraft; Fergus J Couch; Douglas F Easton; Per Hall; Jenny Chang-Claude
Journal:  Breast Cancer Res Treat       Date:  2013-02-20       Impact factor: 4.872

10.  Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.

Authors:  Wulfran Cacheux; Virginie Dangles-Marie; Etienne Rouleau; Julien Lazartigues; Elodie Girard; Adrien Briaux; Pascale Mariani; Sophie Richon; Sophie Vacher; Bruno Buecher; Marion Richard-Molard; Emmanuelle Jeannot; Nicolas Servant; Fereshteh Farkhondeh; Odette Mariani; Thomas Rio-Frio; Sergio Roman-Roman; Emmanuel Mitry; Ivan Bieche; Astrid Lièvre
Journal:  Oncotarget       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.